Boundless Bio, Inc.
NASDAQ:BOLDBiotechnology
+$1.20 today
- Market cap
- $56.67M
- Beta
- 0.97
- P/E (TTM)
- -1.0
- EPS (TTM)
- -$2.50
Volume 0.15M
Average 0.22M
BOLD Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Boundless Bio, Inc.NASDAQ: BOLD
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income declines year over year
Q1 FY2026 net income of $13.56M (cash outflow) fell 14.0% year over year, ahead of the -14.8% change in trailing-twelve-month net income. Sequentially, it rose 5.2% from the prior quarter. Over 3 fiscal years it compounded at +8.2% a year.
Context
- Net income grew in size in 2 of the last 3 fiscal years.
What to watch
Whether net income reaches the consensus estimate of -$53.22M (-8.6%) for the fiscal year ending Dec 2026, a step up from the -11.0% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$13.56M+5.2% QoQ
- Last fiscal yearDec 2025
- -$58.2M-11.0% YoY
- LTMMar 2026
- -$55.99M-14.8% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -14.0% | -14.2% | -0.3 pp |
| 1 year | -11.0% | -8.6% | +2.4 pp |
| 3-year CAGR | +8.2% | -25.1% | -33.3 pp |
| 5-year CAGR | -11.7% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (58.2M) USD
- Year-over-year change
- +11.0%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (58.2M) | +11.0% |
| FY2024 | 2024-12-31 | (65.36M) | -32.2% |
| FY2023 | 2023-12-31 | (49.43M) | -7.7% |
| FY2022 | 2022-12-31 | (45.9M) | -82.1% |
| FY2021 | 2021-12-31 | (25.21M) | — |
Net Income vs competitors
How BOLD compares with its peers on the latest reported figures
- BOLD's LTM Mar 2026 net income of $55.99M is the largest of the 4 companies compared; the peer median is $7.82M.
- Its year-over-year change of -14.8% is the 2nd highest of 4, against a peer median of -23.8%.
- Over three fiscal years its annual growth of +8.2% compares with a peer median of -26.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $55.99M | -14.8% | +8.2% | — | |
| LTM Mar 2026 | $34.55M | -23.8% | -4.9% | — | |
| LTM Mar 2026 | $33.24M | +155.6% | — | 61.9% | |
| LTM Mar 2026 | $7.82M | -83.8% | -48.7% | 911.1% | |
| Peer median (excluding BOLD) | $7.82M | -23.8% | -26.8% | 486.5% | |
Competitors are the stored peer set for BOLD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (25.21M) | (45.9M) | (49.43M) | (65.36M) | (58.2M) |
| Depreciation & Amortization | 682K | 942K | 957K | 1.09M | 1.25M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 1.16M | 2.29M | 3.34M | 7.52M | 6.13M |
| Change in Working Capital | (837K) | 866K | (799K) | (1.68M) | 3.46M |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 0 | 1.91M | 0 | 775K | 1.63M |
| Other Working Capital | (837K) | (1.05M) | (799K) | (2.45M) | 1.83M |
| Other Non-Cash Items | 959K | 2.21M | (915K) | (2.4M) | 698K |
| Operating Cash Flow | (23.25M) | (39.6M) | (46.86M) | (60.84M) | (46.66M) |
| Capital Expenditures | (2.03M) | (1.07M) | (633K) | (2.54M) | (546K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (77.49M) | (42.6M) | (160.12M) | (208.47M) | (174.9M) |
| Sales of Investments | 20.24M | 59.8M | 122.5M | 184.9M | 213.24M |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (59.29M) | 16.13M | (38.26M) | (26.1M) | 37.8M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 0 | 126K | 0 | 93M | 141K |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 208K | 0 | (1.77M) | (3.18M) | 0 |
| Financing Cash Flow | 105.53M | 126K | 97.9M | 89.82M | 141K |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 22.99M | (23.34M) | 12.78M | 2.88M | (8.72M) |
| Free Cash Flow | (25.28M) | (40.66M) | (47.49M) | (63.38M) | (47.21M) |
Boundless Bio, Inc.
NASDAQ:BOLD
Intrinsic Alpha fair value
Locked
Current Price
$2.40
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.